Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors.

Singh R, Fazal Z, Freemantle SJ, Spinella MJ.

Cancer Drug Resist. 2019;2(3):580-594. doi: 10.20517/cdr.2019.19. Epub 2019 Sep 19.

2.

Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors.

Singh R, Fazal Z, Corbet AK, Bikorimana E, Rodriguez JC, Khan EM, Shahid K, Freemantle SJ, Spinella MJ.

Cancers (Basel). 2019 Jun 8;11(6). pii: E796. doi: 10.3390/cancers11060796.

3.

Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target.

Mustachio LM, Lu Y, Kawakami M, Roszik J, Freemantle SJ, Liu X, Dmitrovsky E.

Cancer Res. 2018 Feb 1;78(3):587-592. doi: 10.1158/0008-5472.CAN-17-1752. Epub 2018 Jan 17. Review.

4.

G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer.

Yim CY, Bikorimana E, Khan E, Warzecha JM, Shin L, Rodriguez J, Dmitrovsky E, Freemantle SJ, Spinella MJ.

Cell Cycle. 2017;16(21):2146-2155. doi: 10.1080/15384101.2017.1371884. Epub 2017 Sep 14.

5.

Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.

Mustachio LM, Lu Y, Tafe LJ, Memoli V, Rodriguez-Canales J, Mino B, Villalobos PA, Wistuba I, Katayama H, Hanash SM, Roszik J, Kawakami M, Cho KJ, Hancock JF, Chinyengetere F, Hu S, Liu X, Freemantle SJ, Dmitrovsky E.

Mol Cancer Res. 2017 Jul;15(7):905-914. doi: 10.1158/1541-7786.MCR-16-0369. Epub 2017 Feb 27.

6.

The ISG15-specific protease USP18 regulates stability of PTEN.

Mustachio LM, Kawakami M, Lu Y, Rodriguez-Canales J, Mino B, Behrens C, Wistuba I, Bota-Rabassedas N, Yu J, Lee JJ, Roszik J, Zheng L, Liu X, Freemantle SJ, Dmitrovsky E.

Oncotarget. 2017 Jan 3;8(1):3-14. doi: 10.18632/oncotarget.13914.

7.

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.

Albany C, Hever-Jardine MP, von Herrmann KM, Yim CY, Tam J, Warzecha JM, Shin L, Bock SE, Curran BS, Chaudhry AS, Kim F, Sandusky GE, Taverna P, Freemantle SJ, Christensen BC, Einhorn LH, Spinella MJ.

Oncotarget. 2017 Jan 10;8(2):2949-2959. doi: 10.18632/oncotarget.13811.

8.

Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.

Danilov AV, Hu S, Orr B, Godek K, Mustachio LM, Sekula D, Liu X, Kawakami M, Johnson FM, Compton DA, Freemantle SJ, Dmitrovsky E.

Mol Cancer Ther. 2016 Nov;15(11):2758-2766. Epub 2016 Aug 22.

9.

G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program.

Yim CY, Sekula DJ, Hever-Jardine MP, Liu X, Warzecha JM, Tam J, Freemantle SJ, Dmitrovsky E, Spinella MJ.

Cancer Res. 2016 Mar 1;76(5):1204-13. doi: 10.1158/0008-5472.CAN-15-2265. Epub 2016 Feb 2.

10.

Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.

Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M, Ma T, Burkett SS, Eisenberg BL, Wells WA, Hoopes PJ, Demicco EG, Lazar AJ, Torres KE, Memoli V, Freemantle SJ, Dmitrovsky E.

BMC Cancer. 2015 Nov 10;15:886. doi: 10.1186/s12885-015-1883-8.

11.

Effective capture of circulating tumor cells from a transgenic mouse lung cancer model using dendrimer surfaces immobilized with anti-EGFR.

Myung JH, Roengvoraphoj M, Tam KA, Ma T, Memoli VA, Dmitrovsky E, Freemantle SJ, Hong S.

Anal Chem. 2015 Oct 6;87(19):10096-102. doi: 10.1021/acs.analchem.5b02766. Epub 2015 Sep 10.

12.

All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched.

Busch AM, Galimberti F, Nehls KE, Roengvoraphoj M, Sekula D, Li B, Guo Y, Direnzo J, Fiering SN, Spinella MJ, Robbins DJ, Memoli VA, Freemantle SJ, Dmitrovsky E.

Cancer Biol Ther. 2014 Apr;15(4):463-72. doi: 10.4161/cbt.27821. Epub 2014 Feb 4.

13.

Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.

Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, Freemantle SJ, Dragnev KH, Dmitrovsky E.

Mol Cancer Ther. 2013 Aug;12(8):1545-55. doi: 10.1158/1535-7163.MCT-12-0933. Epub 2013 May 16.

14.

Evidence for tankyrases as antineoplastic targets in lung cancer.

Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ.

BMC Cancer. 2013 Apr 28;13:211. doi: 10.1186/1471-2407-13-211.

15.

Repression of exogenous gene expression by the retinoic acid target gene G0S2.

Ma T, Dong JP, Sekula DJ, Fei DL, Lamph WW, Henderson M, Lu Y, Blumen S, Freemantle SJ, Dmitrovsky E.

Int J Oncol. 2013 May;42(5):1743-53. doi: 10.3892/ijo.2013.1876. Epub 2013 Mar 28.

16.

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.

Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, Benes C, Dmitrovsky E.

Int J Oncol. 2012 Nov;41(5):1751-61. doi: 10.3892/ijo.2012.1599. Epub 2012 Aug 22.

17.

Evidence for the ubiquitin protease UBP43 as an antineoplastic target.

Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, Andrew AS, Memoli V, Dmitrovsky E.

Mol Cancer Ther. 2012 Sep;11(9):1968-77. doi: 10.1158/1535-7163.MCT-12-0248. Epub 2012 Jul 2.

18.

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E.

Cancer Prev Res (Phila). 2011 Jun;4(6):818-28. doi: 10.1158/1940-6207.CAPR-10-0376.

19.

Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells.

Mao P, Hever MP, Niemaszyk LM, Haghkerdar JM, Yanco EG, Desai D, Beyrouthy MJ, Kerley-Hamilton JS, Freemantle SJ, Spinella MJ.

J Biol Chem. 2011 Jun 3;286(22):19381-91. doi: 10.1074/jbc.M111.218040. Epub 2011 Apr 13.

20.

Involvement of microRNAs in lung cancer biology and therapy.

Liu X, Sempere LF, Guo Y, Korc M, Kauppinen S, Freemantle SJ, Dmitrovsky E.

Transl Res. 2011 Apr;157(4):200-8. doi: 10.1016/j.trsl.2011.01.001. Epub 2011 Feb 4. Review.

21.

Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention.

Freemantle SJ, Dmitrovsky E.

Cancer Prev Res (Phila). 2010 Dec;3(12):1513-8. doi: 10.1158/1940-6207.CAPR-10-0297. Review.

22.

MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.

Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, Dragnev KH, Li H, Direnzo J, Bak M, Freemantle SJ, Kauppinen S, Dmitrovsky E.

J Clin Invest. 2010 Apr;120(4):1298-309. doi: 10.1172/JCI39566. Epub 2010 Mar 8.

23.

High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors.

Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E, Spinella MJ.

Cancer Res. 2009 Dec 15;69(24):9360-6. doi: 10.1158/0008-5472.CAN-09-1490.

24.

Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting.

Snow GE, Kasper AC, Busch AM, Schwarz E, Ewings KE, Bee T, Spinella MJ, Dmitrovsky E, Freemantle SJ.

BMC Cancer. 2009 Oct 29;9:383. doi: 10.1186/1471-2407-9-383.

25.

Retinoic acid mediates long-paced oscillations in retinoid receptor activity: evidence for a potential role for RIP140.

Heim KC, Gamsby JJ, Hever MP, Freemantle SJ, Loros JJ, Dunlap JC, Spinella MJ.

PLoS One. 2009 Oct 28;4(10):e7639. doi: 10.1371/journal.pone.0007639.

26.

Uncovering growth-suppressive MicroRNAs in lung cancer.

Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, DiRenzo J, Korc M, Cole CN, Bak M, Kauppinen S, Dmitrovsky E.

Clin Cancer Res. 2009 Feb 15;15(4):1177-83. doi: 10.1158/1078-0432.CCR-08-1355.

27.

Retinoid chemoprevention trials: cyclin D1 in the crosshairs.

Freemantle SJ, Guo Y, Dmitrovsky E.

Cancer Prev Res (Phila). 2009 Jan;2(1):3-6. doi: 10.1158/1940-6207.CAPR-08-0218. Review. No abstract available.

28.

UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation.

Shah SJ, Blumen S, Pitha-Rowe I, Kitareewan S, Freemantle SJ, Feng Q, Dmitrovsky E.

Mol Cancer Ther. 2008 Apr;7(4):905-14. doi: 10.1158/1535-7163.MCT-07-0515.

29.

Selective repression of retinoic acid target genes by RIP140 during induced tumor cell differentiation of pluripotent human embryonal carcinoma cells.

Heim KC, White KA, Deng D, Tomlinson CR, Moore JH, Freemantle SJ, Spinella MJ.

Mol Cancer. 2007 Sep 19;6:57.

30.

Cyclin degradation for cancer therapy and chemoprevention.

Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E.

J Cell Biochem. 2007 Nov 1;102(4):869-77. Review.

PMID:
17868090
31.

The direct p53 target gene, FLJ11259/DRAM, is a member of a novel family of transmembrane proteins.

Kerley-Hamilton JS, Pike AM, Hutchinson JA, Freemantle SJ, Spinella MJ.

Biochim Biophys Acta. 2007 Apr;1769(4):209-19. Epub 2007 Feb 22.

32.

Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas.

Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, Freemantle SJ, Dmitrovsky E.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4089-94. Epub 2007 Feb 27.

33.

Uncovering residues that regulate cyclin D1 proteasomal degradation.

Feng Q, Sekula D, Müller R, Freemantle SJ, Dmitrovsky E.

Oncogene. 2007 Aug 2;26(35):5098-106. Epub 2007 Feb 19.

PMID:
17310991
34.

Repression of cyclin D1 as a target for germ cell tumors.

Freemantle SJ, Vaseva AV, Ewings KE, Bee T, Krizan KA, Kelley MR, Hattab EM, Memoli VA, Black CC, Spinella MJ, Dmitrovsky E.

Int J Oncol. 2007 Feb;30(2):333-40.

PMID:
17203214
35.

Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Giuliano CJ, Freemantle SJ, Spinella MJ.

Curr Cancer Ther Rev. 2006 Aug 1;2(3):255-270.

36.

The retinoic acid paradox in cancer chemoprevention.

Freemantle SJ, Dragnev KH, Dmitrovsky E.

J Natl Cancer Inst. 2006 Apr 5;98(7):426-7. No abstract available.

PMID:
16595769
37.

A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis.

Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, Dragnev KH, Freemantle SJ, Dmitrovsky E.

J Natl Cancer Inst. 2005 Nov 16;97(22):1645-51.

PMID:
16288117
38.

Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity.

Giuliano CJ, Kerley-Hamilton JS, Bee T, Freemantle SJ, Manickaratnam R, Dmitrovsky E, Spinella MJ.

Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. Epub 2005 Sep 1.

PMID:
16168501
39.

Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms.

Ma Y, Feng Q, Sekula D, Diehl JA, Freemantle SJ, Dmitrovsky E.

Cancer Res. 2005 Jul 15;65(14):6476-83.

40.

Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy.

Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ, Dmitrovsky E.

Clin Cancer Res. 2004 Apr 1;10(7):2570-7.

41.

Retinoids in cancer therapy and chemoprevention: promise meets resistance.

Freemantle SJ, Spinella MJ, Dmitrovsky E.

Oncogene. 2003 Oct 20;22(47):7305-15. Review.

PMID:
14576840
42.

Negative feedback at the level of nuclear receptor coregulation. Self-limitation of retinoid signaling by RIP140.

White KA, Yore MM, Warburton SL, Vaseva AV, Rieder E, Freemantle SJ, Spinella MJ.

J Biol Chem. 2003 Nov 7;278(45):43889-92. Epub 2003 Sep 22.

43.

Microarray analysis uncovers retinoid targets in human bronchial epithelial cells.

Ma Y, Koza-Taylor PH, DiMattia DA, Hames L, Fu H, Dragnev KH, Turi T, Beebe JS, Freemantle SJ, Dmitrovsky E.

Oncogene. 2003 Jul 31;22(31):4924-32.

PMID:
12894236
44.

Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2.

Freemantle SJ, Portland HB, Ewings K, Dmitrovsky F, DiPetrillo K, Spinella MJ, Dmitrovsky E.

Gene. 2002 May 29;291(1-2):17-27.

PMID:
12095675
45.
46.

UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.

Kitareewan S, Pitha-Rowe I, Sekula D, Lowrey CH, Nemeth MJ, Golub TR, Freemantle SJ, Dmitrovsky E.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3806-11. Epub 2002 Mar 12.

47.

Clinical link between p53 and angiogenesis in lung cancer.

Freemantle SJ, Dmitrovsky E.

J Clin Oncol. 2002 Feb 15;20(4):883-4. No abstract available.

PMID:
11844804
48.

Cyclin proteolysis as a retinoid cancer prevention mechanism.

Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E.

Ann N Y Acad Sci. 2001 Dec;952:13-22. Review.

PMID:
11795432
49.

Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.

Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, Knauth EA, Beebe JS, Dmitrovsky E.

Clin Cancer Res. 2002 Jan;8(1):54-60.

50.

Transcriptional activation of the nuclear receptor corepressor RIP140 by retinoic acid: a potential negative-feedback regulatory mechanism.

Kerley JS, Olsen SL, Freemantle SJ, Spinella MJ.

Biochem Biophys Res Commun. 2001 Jul 27;285(4):969-75.

PMID:
11467847

Supplemental Content

Loading ...
Support Center